Emcure unit sells mRNA business for ₹1,395 million

Gennova Biopharmaceuticals, a subsidiary of

sold its mRNA business to Immunoscript Life Science for ₹1,395 million. The deal, signed on July 10, 2026, is part of a strategic reorganization to focus on core biotechnology areas. The transaction is expected to close by July 17, 2026, subject to regulatory approvals. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.